Identification of (-)-cis-6-acetyl-4S-(3-chloro-4-fluoro-benzoylamino)- 3,4-dihydro-2,2-dimethyl-2H-benzo[b]pyran-3S-ol as a potential antimigraine agent

Bioorganic and Medicinal Chemistry Letters

Volumn 9, Issue 2, 1999, Pages 285-290

  Chan, Wai N ^a   Evans, John M ^a   Hadley, Michael S ^a   Herdon, Hugh J ^a   Jerman, Jeffrey C ^a   Parsons, Andrew A ^a   Read, Simon J ^a   Stean, Tania O ^a   Thompson, Mervyn ^a   Upton, Neil ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Chromans; Migraine; Polycyclic heterocylic compounds; SB 204269 receptor

Indexed keywords

6 ACETYL (3 CHLORO 4 FLUOROBENZOYLAMINO) 3,4 DIHYDRO 2,2 DIMETHYL 2H BENZO[B]PYRAN 3 OL; ALBUMIN; ANTIMIGRAINE AGENT; BENZAMIDE DERIVATIVE; CARABERSAT; FLUORESCEIN ISOTHIOCYANATE; PLASMA PROTEIN; SUMATRIPTAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CIS TRANS ISOMERISM; CONTROLLED STUDY; DRUG BINDING SITE; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SCREENING; ELECTROCONVULSIVE THERAPY; EXTRAVASATION; INTRAPERITONEAL DRUG ADMINISTRATION; MIGRAINE; MOUSE; NERVE CELL EXCITABILITY; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; SEIZURE THRESHOLD; STEREOCHEMISTRY; TRIGEMINAL NERVE;

ANIMALS; BENZAMIDES; BENZOPYRANS; DOSE-RESPONSE RELATIONSHIP, DRUG; METHYLCELLULOSE; MICE; MIGRAINE DISORDERS; RATS; SEIZURES; SUMATRIPTAN; TEMPERATURE; TIME FACTORS;

ANIMALIA;

EID: 0033579983     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(98)00728-8     Document Type: Article

References (15)

1. Moskowitz, M., Nozaki, K. and Kraig, R. J. Neuroscience, 1993, 13, 1167-1177.
2. Parsons, A.A. Current Opinion Neurol., 1998, 11, 227-231.
3. Blackburn, T.P., Buckingham, R.E., Chan, W.N., Evans, J.M., Hadley, M.S., Thompson, M; Upton, N., Stemp, G. and Vong, A.K. Bioorg. Med. Chem. Lett., 1995, 5 1163 - 1166.
4. Chan, W.N., Evans, J.M., Hadley, M.S., Herdon, H.J., Jerman, J.C., Morgan, H.K.A., Stean, T.O., Thompson, M., Upton, N., and Vong, A.K. J. Med. Chem., 1996, 39, 4537 - 4359.
5. Herdon, H.J., Jerman, J.C., Stean, T.O., Middlemiss, D.N., Chan, W.N., Vong, A.K., Evans, J.M., Thompson, M. and Upton, N. Brit. J. Pharmacol., 1997, 121, 1687 - 1691.
6. Herdon, H., Jerman, J., Stean, T.O., Chan, W., Middlemiss, D.N. and Upton, N. Eur. J. Pharmacol., 1996, 314, R7-R8.
7. Brown, T.H., Campbell, C.A., Chan, W.N., Evans, J.M., Martin, R.T., Stean, T.O., Stemp, G., Stevens, N.C., Thompson, M., Upton, N. and Vong, A.K. Bioorg. Med. Chem. Lett., 1995, 5, 2563 - 2566.
8. Upton, N., Blackburn, T.P., Campbell, C.A., Cooper, D., Evans, M.L., Herdon, H.J., King, P.D., Ray, A.M., Stean, T.O., Chan, W.N., Evans, J.M and Thompson, M. Brit. J. Pharmacol., 1997, 121, 1679 - 1686.
9. 50 values for vehicle-treated controls fell within the range of 12-14mA.
10. 2O), 2.50 (3H, s, COMe), 3.84 (1H, dd, J=9,3Hz, CHOH), 5.62 (1H, dd, J=9,3Hz, CHNH), 6.91 (1H, d, J=9Hz), 6.95 (1H, brd, J=9Hz), 7.23 (1H, t, J=7Hz), 7.75 (1H, m), 7.83 (1H, dd, J-9,2Hz), 7.92 (1H, d, J=2Hz), 7.96 (1H, br, CONH); m/z: 391 (M+,1%), 373 (4), 358 (88), 203 (50), 157 (100).
11. Young, W.B., Silberstein, S.D. and Dayno, J.M. Seminars in Neurology, 1997, 17, 325 - 333.
12. Methods were developed from Spokes, R.A. and Middlefell, V.C. Eur. J.Pharmacol. 1995, 281, 75-79. In brief, SB-220453 (1, 3 or 10mg/kg i.p.) or vehicle was administered to male rats (190-350g). Between 20-25 min later they were anaesthetised (pentobarbitone 60mg/kg i.p.) and administered fluorescein isothiocyanate (FITC-albumin (rat) (50mg/kg i.V.). After a further 10 min the trigeminal ganglion was stimulated for 5 min (1.2mA, 5Hz, 5ms), followed 30 min later by terminal transcardiac perfusion with heparinised saline. Only animals with complete perfusion (post-perfusion FITC-albumin < 4% of pre-perfusion levels) were included for analysis. In separate experiments, sumatriptan (30 or 300ug/kg i.v.) or saline was administered 5 min post FITC-albumin. FITC-albumin was extracted in phosphate buffered saline and determined by Cytofluor plate reader.
13. SCRIP 1998, 2329, 19.
14. Moskowitz, M. and Macfarlane, R. Cerebrovascular and Brain Metabolism Reviews, 1993, 5, 159 - 177.
15. For methods see: "Animal Models in Psychiatry and Neurology". Hannin, I. and Usdin, E. Eds; Pergamon Press, Oxford, 1977.